LOXL2, a copper-dependent amine oxidase, has emerged as a promising therapeutic target in hepatocellular carcinoma (HCC). Increased LOXL2 expression in HCC has been linked with an aggressive phenotype and represents a poor prognostic factor. Here, we focus on the mechanisms through which LOXL2 orchestrates multiple oncogenic functions in HCC development. We performed a review of the current knowledge on the roles LOXL2 performs in the modulation of the HCC tumor microenvironment, formation of premetastatic niches, and epithelial–mesenchymal transition. We also highlighted the complex interplay between LOXL2 and hypoxia, angiogenesis, and vasculogenic mimicry in HCC. At the end of the review, we summarize the current LOXL2 inhibitors and discuss their potential in HCC precision treatment.

Percutaneous transhepatic biliary drainage (PTBD) is a decompression procedure for malignant proximal biliary obstruction. In this research, over a six-year period, 89 patients underwent PTBD procedure for jaundice caused by malignant disease to restart chemotherapy or for palliative intent. Clinical outcomes after PTBD procedure in the two groups of patients, according to the adequate bilirubin decline (ABD) needed for subsequent chemotherapy, are presented in this paper. Survival and logistic regression were plotted and compared using Kaplan–Meier survival multivariate analysis with a long-range test. Results were processed by MEDCALC software. In the series, 58.4% (52/89) of patients were in good performance status (ECOG 0/1), and PTBD was performed with the intention to (re)start chemotherapy. The normalization of the bilirubin level was seen in 23.0% (12/52), but only 15.4% (8/52) received chemotherapy. The median survival time after PTBD was 9 weeks. In patients with ABD that received chemotherapy, the median survival time was 64 weeks, with 30-day mortality of 27.7%, and 6.4% of death within 7 days. The best outcome was in patients with good performance status (ECOG 0–1), low bilirubin (<120 µmol/L) and LDH (<300 µmol/L) levels and elevated leukocytes at the time of the procedures. PTBD is considered in ABD patients who are candidates for chemotherapy.

Background/Objectives: Healthcare institutions, similar to other service providers, should prioritize their clients—in this case, patients—to effectively meet their needs. However, fulfilling this objective becomes increasingly challenging due to numerous factors. Therefore, this study explores student patient satisfaction by examining the effects of environmental quality dimensions (Internal Spaces, External Spaces, And Social Environment) and green practices, as well as investigating how environmental knowledge moderates the relationship between green practices and patient satisfaction. Methods: Given the latent nature of the variables investigated, structural equation modeling (SEM) was employed. Some variables were conceptualized as hierarchical constructs comprising higher-order and lower-order components. Before testing the relationships among variables, reliability and validity assessments were performed. For this purpose, the SmartPLS 4 software was used. Since the focus of the research was on students’ health in general, the sample consisted of 280 students from the University of Novi Sad (Republic of Serbia). Results: Among the three environmental quality dimensions, only the Social Environment had a significant and positive influence on patient satisfaction. Furthermore, the green practices emerged as a significant determinant of patient satisfaction. However, the moderating effect of environmental knowledge on this relationship was found to be non-significant. Conclusions: This research underscores the significance of patient satisfaction as a critical objective for healthcare institutions. Special attention should be directed toward enhancing positive interactions between medical staff and patients and adopting green practices. Consequently, certain managerial aspects related to human resource management (such as adequate staffing and organization of personnel) should be considered. In addition, issues concerning financial challenges and benefits regarding the implementation of green practices in healthcare were presented.

The treatment of patients with metastatic colorectal cancer (mCRC) is complex and is impacted by the location of the primary tumor (LPT). Our study aims to emphasize the importance of LPT as a prognostic and predictive marker as well as to examine the significance of HER2 overexpression in patients with mCRC, particularly in relation to the response to Epidermal Growth Factor Receptor Antibody treatment (anti-EGFR therapy). In this study, 181 patients with Kirsten RAS (KRAS) wild-type mCRC who received anti-EGFR therapy were included. Among them, 101 had left colon cancer (LCC) and 80 had right colon cancer (RCC). Results demonstrated that patients with KRAS wild-type LCC had better median overall survival (OS) (43 vs. 33 months, p = 0.005) and progression-free survival (PFS) (6 vs. 3 months, p < 0.001) compared to those with RCC. Multivariate analysis identified mucinous adenocarcinoma (p < 0.001), RCC location (p = 0.022), perineural invasion (p = 0.034), and tumors at the resection margin (p = 0.001) as independent predictors of OS, while mucinous adenocarcinoma (p = 0.001) and RCC location (p = 0.004) independently correlated with significantly shorter PFS. In addition, human epidermal growth factor receptor 2 (HER2) positive expression was significantly associated with worse PFS compared to HER2 negative results (p < 0.001). In conclusion, LPT is an important marker for predicting outcomes in the treatment of wild-type mCRC using anti-EGFR therapy, since patients with RCC have a statistically significantly shorter PFS and OS. Further investigation is needed to understand the role of HER2 overexpression in wild-type mCRC, as these patients also exhibit shorter survival.

LOXL2, a copper-dependent amine oxidase, has emerged as a promising therapeutic target in hepatocellular carcinoma (HCC). Increased LOXL2 expression in HCC has been linked with aggressive phenotype and represents a poor prognostic factor. Here, we focus on mechanisms by which LOXL2 orchestrates multiple oncogenic functions in HCC development. We are reviewing current knowledge about the roles of LOXL2 in the modulation of the HCC tumor microenvironment, formation of premetastatic niches, and epithelial-mesenchymal transition. Also, we are highlighting the complex interplay between LOXL2 and hypoxia, angiogenesis, and vasculogenic mimicry in HCC. At the end of the review, we summarize current LOXL2 inhibitors and discuss their potential in HCC precision treatment.

Introduction. Pancreatic cancer is among the most aggressive malignancies, with a poor prognosis. The liver, peritoneum, lungs, and distant lymph nodes are the most common metastatic sites. However, metastasis of pancreatic cancer to the large bowel is extremely rare. Case Report. A 48-year-old male with pancreatic cancer underwent radical pancreatosplenectomy in August 2022, accompanied by subtotal gastrectomy, partial resection of the transverse colon, and resection with reconstruction of the splenic vein. He subsequently received six cycles of adjuvant therapy based on the 5-fluorouracil/Leucovorin protocol, which concluded in February 2023. Routine follow-ups revealed multiple liver metastases by June 2023. First-line systemic treatment with the mono-Gemcitabine protocol was initiated, but disease progression occurred after three cycles. The patient then transitioned to second-line therapy with the De Gramont/Cisplatin protocol. During the second cycle, he developed intestinal obstruction necessitating emergency surgery, during which a sigmoidostomy was performed. Intraoperative biopsy of a tumor mass in the sigmoid colon confirmed metastasis of the previously operated pancreatic ductal adenocarcinoma into the colonic wall. Conclusion. Metastasis of invasive ductal pancreatic adenocarcinoma to the colon wall, causing intestinal obstruction, is an extremely rare occurrence, with only a few cases documented in the literature. Histopathological analysis of any colonic mass in patients with a history of pancreatic ductal adenocarcinoma is crucial to differentiate between primary colorectal cancer and metastatic lesions originating from pancreatic cancer.